MedTrace Logo

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

NCT00285415 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-02-05

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.

Conditions

  • Advanced Endometrial Adenocarcinoma, Stage III A, B, C

Interventions

DRUG

Docetaxel and Carboplatin

docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Carilion Clinic

    lead OTHER

Principal Investigators

  • Dennis R Scribner, JR, MD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2012-04-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285415 on ClinicalTrials.gov